Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)

被引：0

作者：

Hutchinson, M. ^{[1
]}

Bar-Or, A. ^{[2
]}

Fox, R. J. ^{[3
]}

Gold, R. ^{[4
]}

Giovannoni, G. ^{[5
]}

Kita, M. ^{[6
]}

O'Gorman, J. ^{[7
]}

Yang, M. ^{[7
]}

Sheikh, S. I. ^{[7
]}

Viglietta, V. ^{[7
]}

Dawson, K. T. ^{[7
]}

机构：

[1] St Vincents Univ Hosp, Dublin 4, Ireland

[2] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada

[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA

[4] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[5] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[6] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[7] Biogen Idec Inc, Weston, MA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：682 / 683

页数：2

共 50 条

[31] EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 CONFIRM STUDY
Kita, M.
Fox, R. J.
Phillips, J. T.
Hutchinson, M.
Havrdova, E.
Sarda, S. P.
Kong, J.
Viglietta, V.
Sheikh, S., I
Dawson, K. T.
VALUE IN HEALTH, 2012, 15 (07) : A556 - A556
[32] Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
Hutchinson, M.
Gold, R.
Fox, R. J.
Havrdova, E.
Giovannoni, G.
Zhang, A.
Hotermans, C.
Stephan, M.
Bar-Or, A.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 235 - 235
[33] Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis
Selmaj, K.
Gold, R.
Kappos, L.
Bar-Or, A.
Arnold, D.
Giovannoni, G.
Sweetser, M.
Novas, M.
Raghupathi, K.
Dawson, K.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S451
[34] EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 DEFINE STUDY
Kappos, L.
Gold, R.
Arnold, D. L.
Bar-Or, A.
Giovannoni, G.
Selmaj, K.
Sarda, S. P.
Agarwal, S.
Zhang, A.
Sheikh, S., I
Dawson, K. T.
VALUE IN HEALTH, 2012, 15 (07) : A557 - A557
[35] Effects of BG-12 on quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
Kita, M.
Fox, R. J.
Phillips, J. T.
Hutchinson, M.
Havrdova, E.
Sarda, S. P.
Kong, J.
Viglietta, V.
Sheikh, S. I.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 254 - 254
[36] Effects of oral BG-12 (Dimethyl Fumarate) on Magnetic Resonance Imaging (Mri) Outcomes in Relapsing-Remitting Multiple Sclerosis (Rrms): an Integrated Analysis of the Phase 3 Define and Confirm Studies
Bar-Or, A.
Arnold, D. L.
Gold, R.
Fox, R. J.
MacManus, D. G.
Yousry, T.
Kurukulasuriya, N. C.
Zhang, R.
Viglietta, V.
Stephan, M.
Dawson, K. T.
Miller, D. H.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1836 - 1836
[37] Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
Nielsen, A. Scott
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2015, 5
[38] THE COST EFFECTIVENESS OF BG-12 (DIMETHYL FUMARATE) FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
Su, W.
Walker, A.
Sarda, S.
Kansal, A. R.
Vicente, C.
Deniz, B.
VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
[39] Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis
Ruggieri, Serena
Tortorella, Carla
Gasperini, Claudio
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 229 - 239
[40] Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
agarwal, Sonalee
Kappos, Ludwig
Gold, Ralf
Arnold, Douglas
Bar-Or, Amit
Giovannoni, Gavin
Selmaj, Krzysztof
Kong, Jessica
Sheikh, Sarah
Dawson, Katherine
NEUROLOGY, 2012, 78

← 1 2 3 4 5 →